1617 related articles for article (PubMed ID: 24297433)
1. Immunosuppressive T-cell antibody induction for heart transplant recipients.
Penninga L; Møller CH; Gustafsson F; Gluud C; Steinbrüchel DA
Cochrane Database Syst Rev; 2013 Dec; (12):CD008842. PubMed ID: 24297433
[TBL] [Abstract][Full Text] [Related]
2. Antibody induction therapy for lung transplant recipients.
Penninga L; Møller CH; Penninga EI; Iversen M; Gluud C; Steinbrüchel DA
Cochrane Database Syst Rev; 2013 Nov; 2013(11):CD008927. PubMed ID: 24282128
[TBL] [Abstract][Full Text] [Related]
3. Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients.
Penninga L; Wettergren A; Wilson CH; Chan AW; Steinbrüchel DA; Gluud C
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD010253. PubMed ID: 24901467
[TBL] [Abstract][Full Text] [Related]
4. Antibody induction versus corticosteroid induction for liver transplant recipients.
Penninga L; Wettergren A; Wilson CH; Chan AW; Steinbrüchel DA; Gluud C
Cochrane Database Syst Rev; 2014 May; 2014(5):CD010252. PubMed ID: 24880007
[TBL] [Abstract][Full Text] [Related]
5. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.
Hill P; Cross NB; Barnett AN; Palmer SC; Webster AC
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004759. PubMed ID: 28073178
[TBL] [Abstract][Full Text] [Related]
6. Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients.
Penninga L; Penninga EI; Møller CH; Iversen M; Steinbrüchel DA; Gluud C
Cochrane Database Syst Rev; 2013 May; (5):CD008817. PubMed ID: 23728681
[TBL] [Abstract][Full Text] [Related]
7. Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients.
Fairfield C; Penninga L; Powell J; Harrison EM; Wigmore SJ
Cochrane Database Syst Rev; 2015 Dec; (12):CD007606. PubMed ID: 26666504
[TBL] [Abstract][Full Text] [Related]
8. Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients.
Webster AC; Wu S; Tallapragada K; Park MY; Chapman JR; Carr SJ
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD004756. PubMed ID: 28731207
[TBL] [Abstract][Full Text] [Related]
9. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
Swiatecka-Urban A
Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
[TBL] [Abstract][Full Text] [Related]
10. Belatacept for kidney transplant recipients.
Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
[TBL] [Abstract][Full Text] [Related]
11. Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients.
Fairfield C; Penninga L; Powell J; Harrison EM; Wigmore SJ
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD007606. PubMed ID: 29630730
[TBL] [Abstract][Full Text] [Related]
12. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-2 receptor antagonists as induction therapy after heart transplantation: systematic review with meta-analysis of randomized trials.
Møller CH; Gustafsson F; Gluud C; Steinbrüchel DA
J Heart Lung Transplant; 2008 Aug; 27(8):835-42. PubMed ID: 18656795
[TBL] [Abstract][Full Text] [Related]
14. Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients.
Webster A; Pankhurst T; Rinaldi F; Chapman JR; Craig JC
Cochrane Database Syst Rev; 2006 Apr; (2):CD004756. PubMed ID: 16625610
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients.
Wagner M; Earley AK; Webster AC; Schmid CH; Balk EM; Uhlig K
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007746. PubMed ID: 26633102
[TBL] [Abstract][Full Text] [Related]
16. Interleukin 2 receptor antagonists for kidney transplant recipients.
Webster AC; Ruster LP; McGee R; Matheson SL; Higgins GY; Willis NS; Chapman JR; Craig JC
Cochrane Database Syst Rev; 2010 Jan; 2010(1):CD003897. PubMed ID: 20091551
[TBL] [Abstract][Full Text] [Related]
17. Antibody induction therapy in renal transplant patients receiving calcineurin-inhibitor immunosuppressive regimens: a comparative review.
Nashan B
BioDrugs; 2005; 19(1):39-46. PubMed ID: 15691216
[TBL] [Abstract][Full Text] [Related]
18. Basiliximab: a review of its use as induction therapy in renal transplantation.
Chapman TM; Keating GM
Drugs; 2003; 63(24):2803-35. PubMed ID: 14664658
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 2 receptor antagonists for kidney transplant recipients.
Webster AC; Playford EG; Higgins G; Chapman JR; Craig J
Cochrane Database Syst Rev; 2004; (1):CD003897. PubMed ID: 14974043
[TBL] [Abstract][Full Text] [Related]
20. Maintenance immunosuppression with intermittent intravenous IL-2 receptor antibody therapy in renal transplant recipients.
Gabardi S; Catella J; Martin ST; Perrone R; Chandraker A; Magee CC; McDevitt-Potter LM
Ann Pharmacother; 2011 Sep; 45(9):e48. PubMed ID: 21811001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
